Potential antimicrobial agents for the treatment of multidrug-resistant tuberculosis

European Respiratory Journal

Volumn 43, Issue 3, 2014, Pages 884-897

  Alsaad, Noor ^a   Wilffert, Bob ^a,b   Van Altena, Richard ^a   De Lange, Wiel C M ^a   Van Der Werf, Tjip S ^a   Kosterink, Jos G W ^a,b   Alffenaar, Jan Willem C ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; COLECALCIFEROL; COTRIMOXAZOLE; CYTOCHROME P450 1A2; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DISULFIRAM; DOXYCYCLINE; ETHAMBUTOL; ISONIAZID; METRONIDAZOLE; PHENOTHIAZINE; PYRAZINAMIDE; RIFAMPICIN; THIORIDAZINE; TIGECYCLINE;

ANIMAL EXPERIMENT; ANTIMICROBIAL ACTIVITY; ANTITUBERCULOUS ACTIVITY; CONTROLLED STUDY; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG PENETRATION; DRUG SAFETY; DRUG SENSITIVITY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NAUSEA AND VOMITING; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; SKIN MANIFESTATION; SYSTEMATIC REVIEW; TREATMENT DURATION;

ANTI-INFECTIVE AGENTS; ANTITUBERCULAR AGENTS; CHEMISTRY, PHARMACEUTICAL; CLINICAL TRIALS AS TOPIC; DISULFIRAM; DOXYCYCLINE; DRUG DESIGN; HUMANS; METRONIDAZOLE; MINOCYCLINE; MYCOBACTERIUM TUBERCULOSIS; PHENOTHIAZINES; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84895560404     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00113713     Document Type: Review

References (93)

1. Keshavjee S, Farmer PE. Tuberculosis, drug resistance, and the history of modern medicine. N Engl J Med 2012; 367: 931-936.
2. Migliori GB, Sotgiu G, D'Ambrosio L, et al. TB and MDR/XDR-TB in European Union and European Economic Area countries: managed or mismanaged? Eur Respir J 2012; 39: 619-625.
3. Skripconoka V, Danilovits M, Pehme L, et al. Delamanid improves outcomes and reduces mortality in multidrugresistant tuberculosis. Eur Respir J 2013; 41: 1393-1400.
4. Leung EC, Leung CC, Kam KM, et al. Transmission of multidrug-resistant and extensively drug-resistant tuberculosis in a metropolitan city. Eur Respir J 2013; 41: 901-908.
5. Orenstein EW, Basu S, Shah NS, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 2009; 9: 153-161.
6. Prabowo SA, Gröschel MI, Schmidt EDL, et al. Targeting multidrug-resistant tuberculosis (MDR-TB) by therapeutic vaccines. Med Microbiol Immunol 2013; 202: 95-104.
7. World Health Organization. WHO Report on the Tuberculosis Epidemic. Geneva, WHO Press, 1997.
8. World Health Organization. Global Tuberculosis Control Report 2010. (WHO/HTM/TB/2010.7). Geneva, WHO Press, 2010.
9. De Lorenzo S, Alffenaar JW, Sotgiu G, et al. Efficacy and safety of meropenem-clavulanate added to linezolid containing regimens in the treatment of MDR-/XDR-TB. Eur Respir J 2013; 41: 1386-1392.
10. World Health Organization. Global Tuberculosis Report 2012. (WHO/HTM/TB/2012.6). Geneva, WHO Press, 2010.
11. Skrahina A, Hurevich H, Zalutskaya A, et al. Alarming levels of drug-resistant tuberculosis in Belarus: results of a survey in Minsk. Eur Respir J 2012; 39: 1425-1431.
12. Louw GE, Warren RM, Gey van Pittius NC, et al. A balancing act: efflux/influx in mycobacterial drug resistance. Antimicrob Agents Chemother 2009; 53: 3181-3189.
13. Miotto P, Cabibbe AM, Mantegani P, et al. Geno Type MTBDRsl performance on clinical samples with diverse genetic background. Eur Respir J 2012; 40: 690-698.
14. Voskuil MI, Schnappinger D, Visconti KC, et al. Inhibition of respiration by nitric oxide induces a Mycobacterium tuberculosis dormancy program. J Exp Med 2003; 198: 705-713.
15. Tomioka H. Current status of some antituberculosis drugs and the development of new antituberculous agents with special reference to their in vitro and in vivo antimicrobial activities. Curr Pharm Des 2006; 12: 4047-4070.
16. Amaral L, Kristiansen JE, Abebe LS, et al. Inhibition of the respiration of multi-drug resistant clinical isolates of Mycobacterium tuberculosis by thioridazine: potential use for initial therapy of freshly diagnosed tuberculosis. J Antimicrob Chemother 1996; 38: 1049-1053.
17. Martins M, Schelz Z, Martins A, et al. In vitro and ex vivo activity of thioridazine derivatives against Mycobacterium tuberculosis. Int J Antimicrob Agents 2007; 29: 338-340.
18. Martins M, Viveiros M, Kristiansen JE, et al. The curative activity of thioridazine on mice infected with Mycobacterium tuberculosis. In Vivo 2007; 21: 771-775.
19. Dinovo EC, Bost RO, Sunshine I, et al. Distribution of thioridazine and its metabolites in human tissues and fluids obtained postmortem. Clin Chem 1978; 24: 1828-1830.
20. Thanacoody HK. Thioridazine: resurrection as an antimicrobial agent? Br J Clin Pharmacol 2007; 64: 566-574.
21. Wayne LG, Sramek HA. Metronidazole is bactericidal to dormant cells of Mycobacterium tuberculosis. Antimicrob Agents Chemother 1994; 38: 2054-2058.
22. Brooks JV, Furney SK, Orme IM. Metronidazole therapy in mice infected with tuberculosis. Antimicrob Agents Chemother 1999; 43: 1285-1288.
23. Filippini P, Iona E, Piccaro G, et al. Activity of drug combinations against dormant Mycobacterium tuberculosis. Antimicrob Agents Chemother 2010; 54: 2712-2715.
24. Klinkenberg LG, Sutherland LA, Bishai WR, et al. Metronidazole lacks activity against Mycobacterium tuberculosis in an in vivo hypoxic granuloma model of latency. J Infect Dis 2008; 198: 275-283.
25. Hoff DR, Caraway ML, Brooks EJ, et al. Metronidazole lacks antibacterial activity in guinea pigs infected with Mycobacterium tuberculosis. Antimicrob Agents Chemother 2008; 52: 4137-4140.
26. Driver ER, Ryan GJ, Hoff DR, et al. Evaluation of a mouse model of necrotic granuloma formation using C3HeB/FeJ mice for testing of drugs against Mycobacterium tuberculosis. Antimicrob Agents Chemother 2012; 56: 3181-3195.
27. Lamp KC, Freeman CD, Klutman NE, et al. Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials. Clin Pharmacokinet 1999; 36: 353-373.
28. Coban AY, Deveci A, Cayci YT, et al. In vitro effect of tigecycline against Mycobacterium tuberculosis and a review of the available drugs for tuberculosis. African J Microbiol Res 2011; 5: 311-315.
29. Zhanel GG, Homenuik K, Nichol K, et al. The glycylcyclines: a comparative review with the tetracyclines. Drugs 2004; 64: 63-88.
30. Conte JE Jr, Golden JA, Kelly MG, et al. Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. Int J Antimicrob Agents 2005; 25: 523-529.
31. Walker NF, Clark SO, Oni T, et al. Doxycycline and HIV infection suppress tuberculosis-induced matrix metalloproteinases. Am J Respir Crit Care Med 2012; 185: 989-997.
32. Balabanova Y, Ruddy M, Hubb J, et al. Multidrug-resistant tuberculosis in Russia: clinical characteristics, analysis of second-line drug resistance and development of standardized therapy. Eur J Clin Microbiol Infect Dis 2005; 24: 136-139.
33. Byrne ST, Gu P, Zhou J, et al. Pyrrolidine dithiocarbamate and diethyldithiocarbamate are active against growing and nongrowing persister Mycobacterium tuberculosis. Antimicrob Agents Chemother 2007; 51: 4495-4497.
34. Hübner L, Ernst M, von Laer D, et al. Enhancement of monocyte antimycobacterial activity by diethyldithiocarbamate (DTC). Int J Immunopharmacol 1991; 13: 1067-1072.
35. Horita Y, Takii T, Yagi T, et al. Antitubercular activity of disulfiram, an antialcoholism drug, against multidrug-and extensively drug-resistant Mycobacterium tuberculosis isolates. Antimicrob Agents Chemother 2012; 56: 4140-4145.
36. Peachey JE, Brien JF, Roach CA, et al. A comparative review of the pharmacological and toxicological properties of disulfiram and calcium carbimide. J Clin Psychopharmacol 1981; 1: 21-26.
37. Forgacs P, Wengenack NL, Hall L, et al. Tuberculosis and trimethoprim-sulfamethoxazole. Antimicrob Agents Chemother 2009; 53: 4789-4793.
38. Huang TS, Kunin CM, Yan BS, et al. Susceptibility of Mycobacterium tuberculosis to sulfamethoxazole, trimethoprim and their combination over a 12 year period in Taiwan. J Antimicrob Chemother 2012; 67: 633-637.
39. Wallace RJ Jr, Nash DR, Steele LC, et al. Susceptibility testing of slowly growing mycobacteria by a microdilution MIC method with 7H9 broth. J Clin Microbiol 1986; 24: 976-981.
40. Vilchèze C, Jacobs WR Jr. The combination of sulfamethoxazole, trimethoprim, and isoniazid or rifampin is bactericidal and prevents the emergence of drug resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2012; 56: 5142-5148.
41. Macingwana L, Baker B, Ngwane AH, et al. Sulfamethoxazole enhances the antimycobacterial activity of rifampicin. J Antimicrob Chemother 2012; 67: 2908-2911.
42. Reeves DS, Wilkinson PJ. The pharmacokinetics of trimethoprim and trimethoprim/sulphonamide combinations, including penetration into body tissues. Infection 1979; 7: Suppl. 4, S330-S341.
43. Ordway D, Viveiros M, Leandro C, et al. Clinical concentrations of thioridazine kill intracellular multidrugresistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 2003; 47: 917-922.
44. Viveiros M, Amaral L. Enhancement of antibiotic activity against poly-drug resistant Mycobacterium tuberculosis by phenothiazines. Int J Antimicrob Agents 2001; 17: 225-228.
45. Tsuneizumi T, Babb SM, Cohen BM. Drug distribution between blood and brain as a determinant of antipsychotic drug effects. Biol Psychiatry 1992; 32: 817-824.
46. Nyberg G, Axelsson R, Martensson E. Binding of thioridazine and thioridazine metabolites to serum proteins in psychiatric patients. Eur J Clin Pharmacol 1978; 14: 341-350.
47. Ginsberg AM. Drugs in development for tuberculosis. Drugs 2010; 70: 2201-2214.
48. Wayne LG, Hayes LG. An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect Immun 1996; 64: 2062-2069.
49. Jensen JC, Gugler R. Single-and multiple-dose metronidazole kinetics. Clin Pharmacol Ther 1983; 34: 481-487.
50. Desai CR, Heera S, Patel A, et al. Role of metronidazole in improving response and specific drug sensitivity in advanced pulmonary tuberculosis. J Assoc Physicians India 1989; 37: 694-697.
51. Cina SJ, Russell RA, Conradi SE. Sudden death due to metronidazole/ ethanol interaction. Am J Forensic Med Pathol 1996; 17: 343-346.
52. Rubinstein E, Vaughan D. Tigecycline: a novel glycylcycline. Drugs 2005; 65: 1317-1336.
53. Wallace RJ Jr, Brown-Elliott BA, Crist CJ, et al. Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria. Antimicrob Agents Chemother 2002; 46: 3164-3167.
54. Muralidharan G, Micalizzi M, Speth J, et al. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob Agents Chemother 2005; 49: 220-229.
55. Alsaad N, van Altena R, Pranger AD, et al. Evaluation of co-trimoxazole in the treatment of multidrug-resistant tuberculosis. Eur Respir J 2013; 42: 504-512.
56. Melmon KL, Carruthers SG, Morrelli HF, et al. Melmon and Morrelli's Clinical Pharmacology: Basic Principles in Therapeutics. 4th Edn. New York, McGraw Hill, 2000.
57. Jarvis WR, ed. Nosocomial Pneumonia. New York, Marcel Dekker, 2000.
58. Abbate E, Vescovo M, Natiello M, et al. Successful alternative treatment of extensively drug-resistant tuberculosis in Argentina with a combination of linezolid, moxifloxacin and thioridazine. J Antimicrob Chemother 2012; 67: 473-477.
59. Sharma S, Singh A. Phenothiazines as anti-tubercular agents: mechanistic insights and clinical implications. Expert Opin Investig Drugs 2011; 20: 1665-1676.
60. Amaral L, Viveiros M, Molnar J. Antimicrobial activity of phenothiazines. In Vivo 2004; 18: 725-731.
61. Amaral L, Viveiros M. Why thioridazine in combination with antibiotics cures extensively drug-resistant Mycobacterium tuberculosis infections. Int J Antimicrob Agents 2012; 39: 376-380.
62. Wójcikowski J, Maurel P, Daniel WA. Characterization of human cytochrome p450 enzymes involved in the metabolism of the piperidine-type phenothiazine neuroleptic thioridazine. Drug Metab Dispos 2006; 34: 471-476.
63. Amaral L, Boeree MJ, Gillespie SH, et al. Thioridazine cures extensively drug-resistant tuberculosis (XDR-TB) and the need for global trials is now!. Int J Antimicrob Agents 2010; 35: 524-526.
64. Mackin P. Cardiac side effects of psychiatric drugs. Hum Psychopharmacol 2008; 23: Suppl. 1, 3-14.
65. Viveiros M, Martins M, Couto I, et al. The in vitro activity of phenothiazines against Mycobacterium avium: potential of thioridazine for therapy of the co-infected AIDS patient. In Vivo 2005; 19: 733-736.
66. Edwards DI. Mechanism of antimicrobial action of metronidazole. J Antimicrob Chemother 1979; 5: 499-502.
67. Rhoades ER, Frank AA, Orme IM. Progression of chronic pulmonary tuberculosis in mice aerogenically infected with virulent Mycobacterium tuberculosis. Tuber Lung Dis 1997; 78: 57-66.
68. Amon I, Amon K, Hüller H. Pharmacokinetics and therapeutic efficacy of metronidazole at different dosages. Int J Clin Pharmacol Biopharm 1978; 16: 384-386.
69. O'Keefe JP, Troc KA, Thompson KD. Activity of metronidazole and its hydroxy and acid metabolites against clinical isolates of anaerobic bacteria. Antimicrob Agents Chemother 1982; 22: 426-430.
70. Ralph ED, Kirby WM. Bioassay of metronidazole with either anaerobic or aerobic incubation. J Infect Dis 1975; 132: 587-591.
71. Schwartz DE, Jeunet F. Comparative pharmacokinetic studies of ornidazole and metronidazole in man. Chemotherapy 1976; 22: 19-29.
72. Clinicaltrials.gov.Metronidazole for pulmonary tuberculosis (South Korea). ClinicalTrials.gov identifier: NCT00425113. http://clinicaltrials.gov/ show/NCT00425113 Date last updated: October 21, 2013.
73. Finegold SM. Metronidazole. Ann Intern Med 1980; 93: 585-587.
74. Sang QX, Jin Y, Newcomer RG, et al. Matrix metalloproteinase inhibitors as prospective agents for the prevention and treatment of cardiovascular and neoplastic diseases. Curr Top Med Chem 2006; 6: 289-316.
75. Vojtova V, Urbanek K. Farmakokinetika tetracyklinu a glycylcyklinu [Pharmacokinetics of tetracyclines and glycylcyclines]. Klin Mikrobiol Infekc Lek 2009; 15: 17-21.
76. Noskin GA. Tigecycline: a new glycylcycline for treatment of serious infections. Clin Infect Dis 2005; 41: Suppl. 5, S303-S314.
77. Smith K, Leyden JJ. Safety of doxycycline and minocycline: a systematic review. Clin Ther 2005; 27: 1329-1342.
78. Maresca A, Carta F, Vullo D, et al. Dithiocarbamates strongly inhibit the b-class carbonic anhydrases from Mycobacterium tuberculosis. J Enzyme Inhib Med Chem 2013; 28: 407-411.
79. Anand SP, Selvaraj P. Effect of 1, 25 dihydroxyvitamin D3 on matrix metalloproteinases MMP-7, MMP-9 and the inhibitor TIMP-1 in pulmonary tuberculosis. Clin Immunol 2009; 133: 126-131.
80. Liu PT, Stenger S, Li H, et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006; 311: 1770-1773.
81. Chick J. Safety issues concerning the use of disulfiram in treating alcohol dependence. Drug Saf 1999; 20: 427-435.
82. Hawser S, Lociuro S, Islam K. Dihydrofolate reductase inhibitors as antibacterial agents. Biochem Pharmacol 2006; 71: 941-948.
83. Harries AD, Zachariah R, Corbett EL, et al. The HIV-associated tuberculosis epidemic-when will we act? Lancet 2010; 375: 1906-1919.
84. Suling WJ, Reynolds RC, Barrow EW, et al. Susceptibilities of Mycobacterium tuberculosis and Mycobacterium avium complex to lipophilic deazapteridine derivatives, inhibitors of dihydrofolate reductase. J Antimicrob Chemother 1998; 42: 811-815.
85. Patel RB, Welling PG. Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole). Clin Pharmacokinet 1980; 5: 405-423.
86. Nightingale CH, Ambrose PG, File TM Jr, eds. Community Acquired Respiratory Infections. New York, Marcel Dekker, Inc., 2003.
87. Smilack JD. Trimethoprim-sulfamethoxazole. Mayo Clin Proc 1999; 74: 730-734.
88. Wiktor SZ, Sassan-Morokro M, Grant AD, et al. Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Cô te d'Ivoire: a randomised controlled trial. Lancet 1999; 353: 1469-1475.
89. Mwaungulu FB, Floyd S, Crampin AC, et al. Cotrimoxazole prophylaxis reduces mortality in human immunodeficiency virus-positive tuberculosis patients in Karonga District, Malawi. Bull World Health Organ 2004; 82: 354-363.
90. Masters PA, O'Bryan TA, Zurlo J, et al. Trimethoprim-sulfamethoxazole revisited. Arch InternMed 2003; 163: 402-410.
91. Mori H, Kuroda Y, Imamura S, et al. Hyponatremia and/or hyperkalemia in patients treated with the standard dose of trimethoprim-sulfamethoxazole. Intern Med 2003; 42: 665-669.
92. Heimpel H, Raghavachar A. Hematological side effects of co-trimoxazole. Infection 1987; 15: Suppl. 5, S248-S253.
93. Barry CE 3rd, Slayden RA, Sampson AE, et al. Use of genomics and combinatorial chemistry in the development of new antimycobacterial drugs. Biochem Pharmacol 2000; 59: 221-231.